ZMZhengwei Ma

Zhengwei Ma

*This is an algorithmically generated author record based on publicly available information.

Zhengwei Ma has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Krüppel-Like Factor 5 Is Upregulated by NF-κB To Promote Maladaptive Kidney Repair and CKD Progression

    by Zhengwei Ma, Xiaoru Hu, Santhakumar Manicassamy, Hui Cai, Zheng Dong

    Key Points: Krüppel-like factor 5 was transcriptionally induced in renal proximal and nonproximal tubular cells in mouse models of maladaptive kidney repair and human CKD biopsies. NF-κB mediated Krüppel-like factor 5 induction in maladaptive kidney repair by directly binding to its gene promoter. Upon induction, Krüppel-like factor 5 contributed to maladaptive kidney repair and CKD development by inducing chronic inflammation, cellular senescence, and fibrosis. Background: Maladaptive repair following AKI leads to CKD, but the underlying molecular drivers remain incompletely understood. Krüppel-like factor 5 (Klf5), a zinc finger transcription factor, is upregulated in kidney diseases. However, its role and regulation in postinjury kidney repair are unknown. Methods: Klf5 expression was analyzed in C57BL/6 mice after unilateral ischemia/reperfusion, repeated low-dose cisplatin, and unilateral ureteral obstruction in vivo in human CKD biopsies and in TGF β -, TNF α -, and RLDC-treated kidney proximal tubule cells in vitro . The role of Klf5 was investigated using Klf5 knockdown proximal tubular cells in vitro and proximal tubule–specific Klf5 -knockout mouse models in vivo . To examine the regulation by NF-κB, p65 (RelA, a key component of the NF-κB complex) was specifically ablated from kidney proximal tubule cells in mice. Results: Klf5 was transcriptionally induced in renal proximal tubular cells in mouse models of maladaptive kidney repair and in human CKD biopsies. Proximal tubule–specific Klf5 knockout significantly reduced fibrosis, inflammation, dedifferentiation, and cellular senescence in postinjury kidneys, leading to improved kidney repair. Genetic or pharmacologic inhibition of NF-κB attenuated Klf5 expression and downstream fibrotic and inflammatory responses. NF-κB was further proved to transactivate Klf5 by promoter binding. Conclusions: The results demonstrated Klf5 as a critical mediator of maladaptive repair and CKD development after AKI. Mechanistically, Klf5 was transcriptionally upregulated by NF-κB. Upon induction, Klf5 contributed to renal inflammation, senescence, and fibrosis, highlighting potential therapeutic targets.

  • Top Cited Papers
    Open Access

    Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity

    by Siyao Li, Man J. Livingston, Zhengwei Ma, Xiaoru Hu, Lu Wen, Han-Fei Ding, Daohong Zhou, Zheng Dong

    Cisplatin is a widely used chemotherapy drug; however, it induces both acute and chronic kidney diseases (CKD) in patients with cancer. The pathogenesis of cisplatin-induced CKD is unclear, and effective renoprotective approaches are not available. Here, we report that repeated low-dose cisplatin (RLDC) treatment of C57BL/6 mice induced chronic cellular senescence in kidney tubules, accompanied with tubular degeneration and profibrotic phenotype transformation that culminated in maladaptive repair and renal fibrosis. Suppression of tubular senescence by senolytic drugs ABT-263 and Fisetin attenuated renal fibrosis and improved tubular repair, as indicated by restoration of tubular regeneration and renal function. In vitro, RLDC also induced senescence in mouse proximal tubular (BUMPT) cells. ABT-263 eliminated senescent BUMPT cells following RLDC treatment, reversed the profibrotic phenotype of the cells, and increased their clonogenic activity. Moreover, ABT-263 alleviated the paracrine effect of RLDC-treated BUMPT cells on fibroblasts for fibrosis. Consistently, knockdown of p16 suppressed post-RLDC senescence and fibrotic changes in BUMPT cells and alleviated their paracrine effects on renal fibroblast proliferation. These results indicate that persistent induction of tubular senescence plays an important role in promoting cisplatin-induced CKD. Targeting senescent tubular cells may be efficient for improvement of kidney repair and for the prevention and treatment of cisplatin-induced CKD.


  • Fibroblast Growth Factor 2 Is Produced By Renal Tubular Cells to Act as a Paracrine Factor in Maladaptive Kidney Repair After Cisplatin Nephrotoxicity

    by Xiaoru Hu, Zhengwei Ma, Siyao Li, Lu Wen, Yuqing Huo, Guangyu Wu, Santhakumar Manicassamy, Zheng Dong


  • Open Access

    p53 in Proximal Tubules Mediates Chronic Kidney Problems after Cisplatin Treatment

    by Shuangshuang Fu, Xiaoru Hu, Zhengwei Ma, Qingqing Wei, Xiaohong Xiang, Siyao Li, Lu Wen, Yumei Liang, Zheng Dong

    Nephrotoxicity is a major side-effect of cisplatin in chemotherapy, which can occur acutely or progress into chronic kidney disease (CKD). The protein p53 plays an important role in acute kidney injury induced by cisplatin, but its involvement in CKD following cisplatin exposure is unclear. Here, we address this question by using experimental models of repeated low-dose cisplatin (RLDC) treatment. In mouse proximal tubular BUMPT cells, RLDC treatment induced p53 activation, apoptosis, and fibrotic changes, which were suppressed by pifithrin-α, a pharmacologic inhibitor of p53. In vivo, chronic kidney problems following RLDC treatment were ameliorated in proximal tubule-specific p53-knockout mice (PT-p53-KO mice). Compared with wild-type littermates, PT-p53-KO mice showed less renal damage (KIM-1 positive area: 0.97% vs. 2.5%), less tubular degeneration (LTL positive area: 15.97% vs. 10.54%), and increased proliferation (Ki67 positive area: 2.42% vs. 0.45%), resulting in better renal function after RLDC treatment. Together, these results indicate that p53 in proximal tubular cells contributes significantly to the development of chronic kidney problems following cisplatin chemotherapy.


  • Single-Nucleus Transcriptional Profiling of Chronic Kidney Disease after Cisplatin Nephrotoxicity

    by Zhengwei Ma, Xiaoru Hu, Han-Fei Ding, Ming Zhang, Yuqing Huo, Zheng Dong


  • Open Access

    Autophagy in Cisplatin Nephrotoxicity during Cancer Therapy

    by Xiaoru Hu, Zhengwei Ma, Lu Wen, Siyao Li, Zheng Dong

    Cisplatin is a widely used chemotherapeutic agent but its clinical use is often limited by nephrotoxicity. Autophagy is a lysosomal degradation pathway that removes protein aggregates and damaged or dysfunctional cellular organelles for maintaining cell homeostasis. Upon cisplatin exposure, autophagy is rapidly activated in renal tubule cells to protect against acute cisplatin nephrotoxicity. Mechanistically, the protective effect is mainly related to the clearance of damaged mitochondria via mitophagy. The role and regulation of autophagy in chronic kidney problems after cisplatin treatment are currently unclear, despite the significance of research in this area. In cancers, autophagy may prevent tumorigenesis, but autophagy may reduce the efficacy of chemotherapy by protecting cancer cells. Future research should focus on developing drugs that enhance the anti-tumor effects of cisplatin while protecting kidneys during cisplatin chemotherapy.


  • p53/microRNA-214/ULK1 axis impairs renal tubular autophagy in diabetic kidney disease

    by Zhengwei Ma, Lin Li, Man J. Livingston, Dongshan Zhang, Qingsheng Mi, Ming Zhang, Han-Fei Ding, Yuqing Huo, Changlin Mei, Zheng Dong

    Dysregulation of autophagy in diabetic kidney disease (DKD) has been reported, but the underlying mechanism and its pathogenic role remain elusive. We show that autophagy was inhibited in DKD models and in human diabetic kidneys. Ablation of autophagy-related gene 7 (Atg7) from kidney proximal tubules led to autophagy deficiency and worse renal hypertrophy, tubular damage, inflammation, fibrosis, and albuminuria in diabetic mice, indicating a protective role of autophagy in DKD. Autophagy impairment in DKD was associated with the downregulation of unc-51–like autophagy-activating kinase 1 (ULK1), which was mediated by the upregulation of microRNA-214 (miR-214) in diabetic kidney cells and tissues. Ablation of miR-214 from kidney proximal tubules prevented a decrease in ULK1 expression and autophagy impairment in diabetic kidneys, resulting in less renal hypertrophy and albuminuria. Furthermore, blockade of p53 attenuated miR-214 induction in DKD, leading to higher levels of ULK1 and autophagy, accompanied by an amelioration of DKD. Compared with nondiabetic samples, renal biopsies from patients with diabetes showed induction of p53 and miR-214, associated with downregulation of ULK1 and autophagy. We found a positive correlation between p53/miR-214 and renal fibrosis, but a negative correlation between ULK1/LC3 and renal fibrosis in patients with diabetes. Together, these results identify the p53/miR-214/ULK1 axis in autophagy impairment in diabetic kidneys, pinpointing possible therapeutic targets for DKD.